Welcome to NGC. Skip directly to: Search Box, Navigation, Content.
A direct comparison of the United Stated Preventive Services Task Force (USPSTF), Department of Veteran Affairs, Department of Defense (VA/DoD), and University of Michigan Health System (UMHS) recommendations for tobacco use cessation and prevention is provided in the tables below. Table 1 provides the scope of the guidelines, Table 2 compares the major recommendations, and Table 3 compares the potential benefits and harms of implementing the recommendations. Definitions for the levels of evidence used to support the guideline recommendations are given in Table 4.
The comparison in Table 2 is restricted to recommendations for interventions to be carried out by physicians and/or other health care professionals.
Following the tables and discussion of content comparison, the areas of agreement and differences among the guidelines are identified. In general, the timing of guideline development with respect to available data is an important factor to consider when evaluating areas of differences among the guidelines. Interpretation of available data is also considered.
Related Guidelines
Listed below are common abbreviations used within the tables and discussions:
TABLE 2: RECOMMENDATIONS FOR TOBACCO USE CESSATION AND PREVENTION | |
---|---|
SCREENING AND ASSESSMENT | |
Screening for Tobacco Use | |
USPSTF (2003) |
The USPSTF strongly recommends that clinicians screen all adults for tobacco use and provide tobacco cessation interventions for those who use tobacco products (A recommendation). Clinics that implement screening systems designed to regularly identify and document a patient's tobacco use status increased their rates of clinician intervention, although there is limited evidence for the impact of screening systems on tobacco cessation rates. |
VA/DoD (2004) |
Patients should be asked about tobacco use at most visits, as repeated screening increases rates of clinical intervention. [A]
Background. In order to assess tobacco use status, all patients should be asked about their use of tobacco (including the use of tobacco in any form) upon visiting any provider. This may be accomplished when the patient's vital signs are taken. The tobacco use status should be noted in the patient's record. If the medical record indicates that the patient has never used tobacco or has not used it for many years, repeated assessment is not necessary. |
UMHS (2006) |
Ask all patients about smoking status and assess smoker's readiness to quit. Smoking status should be documented in the medical record. Techniques to remind the physician of a patient's smoking status include smoking status stickers, listing tobacco use on active problem list of tobacco status as part of vital signs. |
Willingness to Quit and Motivational Strategies | |
USPSTF (2003) |
Helpful aspects of counseling include providing problem-solving guidance for smokers to develop a plan to quit and to overcome common barriers to quitting and providing social support within and outside of treatment. Common practices that complement this framework include motivational interviewing, the 5 R's used to treat tobacco use (relevance, risks, rewards, roadblocks, repetition), assessing readiness to change, and more intensive counseling and/or referrals for quitters needing extra help. Telephone "quit lines" have also been found to be an effective adjunct to counseling or medical therapy. |
VA/DoD (2004) |
Assess Willingness to Quit Tobacco users should be assessed for willingness to quit at every visit. [C]
Background. Tobacco users should be given advice appropriate to their level of interest in quitting. Approximately 70 percent of tobacco users want to quit. The patient's level of interest will determine subsequent steps to be taken. By knowing the person's stage of willingness to quit tobacco use, the health care provider can decide whether to provide motivational material to quit tobacco use or, alternatively, specific instructions to help the person quit. Promote Motivation to Quit Tobacco users who are not willing to quit at this time should receive brief, non-judgmental motivational counseling designed to increase their motivation to quit, to include discussion about [Expert Consensus]:
Use of motivational intervention should be considered. This technique has been shown to be beneficial in motivating and changing behaviors of individuals with other substance use dependencies, including some evidence in cessation of smoking. [B] |
UMHS (2006) |
Assess whether the patient is "ready to attempt to quit." If "no," offer motivational interventions using the 5 "R's"
|
TREATMENT STRUCTURE AND INTENSITY | |
Advise Tobacco Users to Quit | |
USPSTF (2003) |
Advise smokers to quit through clear personalized messages. |
VA/DoD (2004) |
Tobacco users should be advised to quit at every visit because there is a dose-response relationship between number of contacts and abstinence. [A] Background. Every health care team member should urge every tobacco user to quit. Repeated messages on the importance of quitting made over time have an accumulated effect on encouraging patients to quit. |
UMHS (2006) |
Advise all smokers to seriously consider making a quit attempt using a clear, strong, and personalized message. |
Intensity of Clinical Interventions | |
USPSTF (2003) |
Brief tobacco cessation counseling interventions, including screening, brief counseling (3 minutes or less), and/or pharmacotherapy, have proven to increase tobacco abstinence rates, although there is a dose-response relationship between quit rates and the intensity of counseling. Effective interventions may be delivered by a variety of primary care clinicians. |
VA/DoD (2004) |
Background. This message should be delivered in the brief "advice" format such that it is clear, (e.g., "I think it is important for you to quit tobacco use now and I can help you."), concise, strong, (e.g., "As your clinician I want you to know that quitting tobacco use is the most important thing you could do to protect your health.") and personalized (e.g., "Quitting your tobacco use will help improve your [health symptom or specific disease]"). |
UMHS (2006) |
Advice as brief as 3 minutes is effective in smoking cessation [A]. In addition to clinician counseling in the office, intensive counseling (frequently defined as a minimum of weekly meeting for the first 4 to 7 weeks of cessation) significantly enhances cessation rates. However, participation in intensive counseling is based largely on patients' motivation to quit and ability to pay [C]. |
Follow-up Assessment and Procedures (Prevention of Relapse) | |
USPSTF (2003) |
Arrange follow-up and support (after assisting in quitting). |
VA/DoD (2004) |
Arrange Follow-up Tobacco users who receive a tobacco cessation intervention should be scheduled for ongoing follow-up for abstinence. [B] Follow-up should be documented and should:
Tobacco users who relapse should be assessed for willingness to make another quit attempt and offered repeated interventions. [B] Tobacco users should be tracked to increase the systematic delivery of interventions for tobacco cessation and increase the likelihood of long-term abstinence. [B] Background. Tobacco dependence is a chronic disease that often requires repeated interventions. Tobacco addiction is a chronic disorder that carries with it the vulnerability to relapse persisting for weeks, months, and perhaps even years. Therefore, consistent follow-up is necessary to ensure optimal care. Initiate/Reinforce Relapse Prevention
Background. Tobacco use is characterized as a chronic relapsing disorder due to the high number of relapses after a single quit attempt. Studies have documented that smokers may make between 3 and 7 serious quit attempts before successfully quitting. Relapse frequently occurs within a few hours or up to 3 months after quitting, and may even occur after a year or more of abstinence. Addressing the issue of relapse before it occurs and identifying risk factors has been helpful in devising coping strategies to help the tobacco user to quit and prepare them to accept relapse as a learning experience and not a failure. Assess Risk for Relapse
Relapse
|
UMHS (2006) |
Arrange follow-up either with phone call or office visit. Follow-up contact should occur soon after the quit date, preferably during the first week [C]. Extending treatment contacts over a number of weeks appears to increase cessation rates [D]. Further follow-up as needed. For abstinent patients, prevent relapse by
For smoking patients:
|
TREATMENT ELEMENTS | |
Counseling and Behavioral Therapies | |
USPSTF (2003) |
Helpful aspects of counseling include providing problem-solving guidance for smokers to develop a plan to quit and to overcome common barriers to quitting and providing social support within and outside of treatment. Common practices that complement this framework include motivational interviewing, the 5 R's used to treat tobacco use (relevance, risks, rewards, roadblocks, repetition), assessing readiness to change, and more intensive counseling and/or referrals for quitters needing extra help. Telephone "quitlines" have also been found to be an effective adjunct to counseling or medical therapy. |
VA/DoD (2004) |
Initiate Counseling Counseling in the Clinic Tobacco users who are willing to quit should receive some form of counseling. There is a dose-response relationship in counseling and rate of abstinence. [A]
Effective counseling can be delivered in multiple formats (e.g., group counseling, proactive telephone counseling, and individual counseling) and may be more effective when combined. [A] Counseling should be provided by a variety of clinician types (physicians or nonphysician clinicians, such as nurses, dentists, dental hygienists, psychologists, pharmacists, and health educators) to increase quit rates. [A] All patients who are willing to quit should have access to intensive counseling (Quitlines or intensive cessation program). Quitlines Tobacco users who are willing to quit may receive counseling via telephone Quitlines, as proactive telephone counseling has been demonstrated to be effective. Pharmacotherapy still needs to be coordinated by the primary care provider. [A] Background. There is strong evidence that behavioral interventions work. More intense interventions, as defined by face-to-face contact, using a multidisciplinary approach and multiple formats, result in better cessation outcomes. However, even brief counseling increases overall abstinence rates. Effective counseling can also be provided by a wide variety of health care professionals, in addition to the patient's primary care physician. Tobacco use counseling and treatment can be provided in a variety of settings. It is crucial that the provider ensures that the tobacco user receives counseling and medication to assist him/her in quitting, regardless of the setting. Counseling tobacco users should start with having the patient set a quit date. Counseling and behavioral tobacco use cessation interventions should include: (1) providing practical counseling (problem-solving skills/skills training), (2) providing social support as part of treatment, and (3) helping tobacco users obtain social support outside of treatment. These three types of counseling and behavior therapies result in higher abstinence rates. Proactive telephone counseling, such as that provided by a Quitline, is another effective option for providing counseling to tobacco users. Note: Aversive smoking interventions (rapid smoking, rapid puffing, other aversive smoking techniques) increase abstinence rates and may be used with smokers who desire such treatment or who have been unsuccessful using other interventions. [B] Although aversive smoking has been demonstrated to be effective, it is rarely used due to the availability of medication. |
UMHS (2006) |
Refer patients interested in quitting within 30 days to a tobacco treatment specialist or other appropriate tobacco cessation program. Alternatively, health care providers can directly provide the following treatment:
|
Adjunctive Pharmacotherapy | |
USPSTF (2003) |
FDA-approved pharmacotherapy that has been identified as safe and effective for treating tobacco dependence includes several forms of NRT (i.e., nicotine gum, nicotine transdermal patches, nicotine inhaler, and nicotine nasal spray) and sustained-release bupropion. Other medications, including clonidine and nortriptyline, have been found to be efficacious and may be considered. Combination Therapy There are fair quality studies showing that combining the nicotine patch with either the gum or nasal spray is more efficacious than using a single form of nicotine replacement therapy alone. |
VA/DoD (2004) |
Tobacco users attempting to quit should be prescribed one or more effective first-line pharmacotherapies for tobacco use cessation. [A]
Tobacco users who do not respond to first-line therapies should:
Combination Therapy Combination therapy may be effective for patients unable to quit with a single first-line agent. [B]
Note:
|
UMHS (2006) |
Nicotine replacement therapies (NRTs), bupropion hydrochloride (Zyban), and varenicline (Chantix®) have been shown to significantly improve cessation rates [A]. Therefore, pharmacologic therapy should be recommended to all patients except in the presence of specific contraindications. Bupropion and varenicline are the two non-nicotine products with FDA approval for smoking cessation. Non-FDA approved agents with potential benefit in smoking cessation include nortriptyline and clonidine. These drugs may best be used as second-line agents when patients cannot take or do not wish to take either NRT, bupropion, or varenicline [D]. Combination Therapy Given the additional cost of dual therapies (e.g., patch plus gum; patch plus inhaler; patch plus nasal spray) and limited benefit, combining NRT is best reserved for highly addicted smokers with several previous failed quit attempts [D]. |
CONSIDERATIONS IN SPECIAL POPULATIONS | |
Pregnancy and Second-hand Smoke Exposure in Infants and Children | |
USPSTF (2003) |
The USPSTF strongly recommends that clinicians screen all pregnant women for tobacco use and provide augmented pregnancy-tailored counseling to those who smoke (A recommendation). The USPSTF found good evidence that extended or augmented smoking cessation counseling (5-15 minutes) using messages and self-help materials tailored for pregnant smokers, compared with brief generic counseling interventions alone, substantially increases abstinence rates during pregnancy, and leads to increased birth weights. Although relapse rates are high in the post-partum period, the USPSTF concluded that reducing smoking during pregnancy is likely to have substantial health benefits both for the baby and the expectant mother. The USPSTF concluded that the benefits of smoking cessation counseling outweigh any potential harms. There is little evidence on the safety and efficacy of tobacco cessation pharmacotherapy for the pregnant woman, the fetus, or the nursing mother and child. Therefore, pharmacotherapy for pregnant women may be considered when the likelihood of quitting and its potential benefits outweighs the risks of the therapy and continued smoking. |
VA/DoD (2004) |
The guideline refers to recommendations offered in DoD/VA Clinical Practice Guideline for Management of Uncomplicated Pregnancy regarding smoking cessation and pregnancy. Specific recommendations from this guideline include:
Background. Smoking in pregnancy presents risks for both the woman and the fetus. Tobacco use by pregnant women has been shown to cause adverse fetal outcomes, including stillbirths, spontaneous abortions, decreased fetal growth, premature births, low birth weight, placental abruption, sudden infant death syndrome (SIDS), cleft palates and cleft lips, and childhood cancers. Many women are motivated to quit during pregnancy, and health care professionals can take advantage of this motivation by reinforcing the knowledge that cessation will reduce health risks to the fetus and that there are postpartum benefits for both the mother and child. Even women who have maintained total abstinence from tobacco for 6 or more months during pregnancy have a high rate of relapse in the postpartum period. Postpartum relapse may be decreased by continued emphasis on the relationship between maternal smoking and poor health outcomes in infants and children (i.e., SIDS, respiratory infections, asthma, and middle ear disease). |
UMHS (2006) |
Pregnant Patients Intensive counseling interventions increase quit rates during pregnancy [A]. If intensive counseling is not possible, brief in-office counseling still has a beneficial effect and should be offered. Few studies have addressed the safety of NRT or bupropion in pregnancy directly; however, studies show that less nicotine and fewer metabolites cross the placenta with the use of NRT than with smoking itself. Therefore cautious use of bupropion with NRT (especially nicotine gum) may be considered after reviewing risks and benefits with the patient. Breastfeeding Women Smoking leads to a significant reduction in breast milk volume and increases the likelihood of early discontinuation [A]. Data support the use of bupropion plus NRT in nursing mothers, with increased cessation rates. The safety profile is favorable, as less nicotine and fewer metabolites are found in breast milk with NRT, compared to smoking more than a half a pack per day. Additionally, eliminating environmental exposure to the infant is a favorable outcome. It is not known whether varenicline is excreted in human milk. |
Children and Adolescents: Screening and Prevention of Initiation of Smoking | |
USPSTF (2003) |
The USPSTF concludes that the evidence is insufficient to recommend for or against routine screening for tobacco use or interventions to prevent and treat tobacco use and dependence among children or adolescents (I recommendation). The USPSTF found limited evidence that screening and counseling children and adolescents in the primary care setting are effective in either preventing initiation or promoting cessation of tobacco use. |
VA/DoD (2004) |
Pediatric and adolescent patients and their parents should be screened by health care providers for tobacco use and provided a strong message regarding the importance of total abstinence from tobacco use. [Expert Consensus] Health care providers in a pediatric setting should advise parents to quit smoking to limit their children's exposure to second-hand smoke. [A] Health care providers in a pediatric setting should offer smoking cessation advice and interventions to parents to improve the parent's chance of quitting use of tobacco. [C] |
UMHS (2006) |
No recommendations offered. |
Children and Adolescents: Counseling and Treatment of Tobacco-dependence | |
USPSTF (2003) |
The USPSTF concludes that the evidence is insufficient to recommend for or against routine screening for tobacco use or interventions to prevent and treat tobacco use and dependence among children or adolescents (I recommendation). The USPSTF found limited evidence that screening and counseling children and adolescents in the primary care setting are effective in either preventing initiation or promoting cessation of tobacco use. The USPSTF found that school- and classroom-based smoking cessation programs may be more effective than no intervention among tobacco users who attend these programs. As with tobacco cessation programs for adults in the community setting, programs with a greater number of counseling sessions and increasing intensity of follow-up had higher quit rates. There is little evidence on the safety and efficacy of tobacco cessation pharmacotherapy in children or adolescents. |
VA/DoD (2004) |
Adolescents who use tobacco and are interested in quitting should be offered counseling and behavioral interventions that were developed for adolescents. [A] Counseling and behavioral interventions shown to be effective with adults may be considered for use with adolescents. [Expert Consensus] When treating adolescents, providers may consider prescriptions for bupropion SR or NRT when there is evidence of nicotine dependence and desire to quit tobacco use. [Expert Consensus] |
UMHS (2006) |
NRT or bupropion may be considered for use in adolescent smokers [D]. While the evidence indicates that these therapies are safe, they seem to be more effective when coupled with counseling. Some studies demonstrate that smoking cessation counseling in the primary care setting can improve adolescent smokers' quit rates [A]. |
Gender Concerns, Racial/Ethnic Minorities, Patients with Psychiatric Cofactors, Older Smokers, and Hospitalized Patients | |
USPSTF (2003) |
No recommendations offered. |
VA/DoD (2004) |
Military Recruits and Trainees Prevent relapse of basic trainees who quit using tobacco as a result of their participation in basic military training.
Hospitalized Patients Encourage all health care team members to advise hospitalized tobacco users to quit and provide tobacco cessation treatment.
Older Patients Encourage all health care team members to advise older tobacco users to quit and provide tobacco cessation treatment.
Psychiatric/Mental Health Patient Provide effective tobacco cessation services to patients with psychiatric comorbidities
|
UMHS (2006) |
Gender Concerns Smoking cessation treatments are shown to benefit both women and men [B]. Two studies suggest that some treatments are less efficacious in women than in men. Women may face different stressors and barriers to quitting (e.g., greater likelihood of depression, greater weight control concerns, and hormonal cycles). This research suggests cessation programs that address these issues would be more effective in treating women [D]. Racial/Ethnic Minorities Smoking cessation treatment has been shown to be effective across both racial and ethnic minorities [A]. Little research has examined intervention specifically designed for a particular ethnic or racial group; however, it is recommended that, when possible, smoking cessation treatment should be tailored to the specific ethnic or racial population with which they are used [C]. It is essential that counseling or self-help materials be conveyed in a language understood by the smoker. Psychiatric Cofactors If presence of psychiatric cofactors, such as depression, eating disorder, anxiety disorder, attention deficit disorder, or alcohol abuse, strongly consider referral to intensive counseling [B]. Treatment of cofactors must be undertaken in preparation for smoking cessation. Older Smokers Smoking cessation treatment has been shown to be effective for older adults and should be provided, as cessation improves pulmonary function and cerebral circulation [A]. Several studies have found cessation rates among motivated older adults similar to those for younger adults; however, supportive counseling and social support may be of more value to prevent relapse than education or skills training [A]. Hospitalized Smokers Providing hospitalized patients with high-intensity behavioral counseling and follow-up of at least 30 days has been shown to increase cessation rates [A]. NRT supplementation can also be useful in this population. Briefer interventions (<20 minutes, delivered only during the hospitalization) have not yet been shown to be helpful. Additional treatment can include self-help brochures or audio/video tapes, chart prompts reminding physicians to advise for cessation, pharmacologic therapy, hospital counseling, and post-discharge counseling telephone calls. Hospitalization should be used as a springboard to promote smoking cessation. |
TABLE 4. EVIDENCE RATING SCHEMES AND REFERENCES | |
---|---|
USPSTF (2003) |
Definitions The Task Force grades its recommendations according to one of 5 classifications (A, B, C, D, I) reflecting the strength of evidence and magnitude of net benefit (benefits minus harms): A The USPSTF strongly recommends that clinicians provide [the service] to eligible patients. The USPSTF found good evidence that [the service] improves important health outcomes and concludes that benefits substantially outweigh harms. B The USPSTF recommends that clinicians provide [this service] to eligible patients. The USPSTF found at least fair evidence that [the service] improves important health outcomes and concludes that benefits outweigh harms. C The USPSTF makes no recommendation for or against routine provision of [the service]. The USPSTF found at least fair evidence that [the service] can improve health outcomes but concludes that the balance of benefits and harms is too close to justify a general recommendation. D The USPSTF recommends against routinely providing [the service] to asymptomatic patients. The USPSTF found at least fair evidence that [the service] is ineffective or that harms outweigh benefits. I The USPSTF concludes that the evidence is insufficient to recommend for or against routinely providing [the service]. Evidence that [the service] is effective is lacking, of poor quality, or conflicting and the balance of benefits and harms cannot be determined. The USPSTF grades the quality of the overall evidence for a service on a 3-point scale (good, fair, poor): Good Evidence includes consistent results from well-designed, well-conducted studies in representative populations that directly assess effects on health outcomes. Fair Evidence is sufficient to determine effects on health outcomes, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence on health outcomes. Poor Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information on important health outcomes. |
VA/DoD (2004) |
Quality of Evidence (QE) I: Evidence obtained from at least one properly randomized controlled trial II-1: Evidence obtained from well-designed controlled trails without randomization II-2: Evidence obtained from well-designed cohort or case-control analytic studies II-3: Evidence obtained from multiple time series, dramatic results in uncontrolled experiments III: Opinions of respected authorities; case reports, and reports of expert committees Overall Quality Good: High grade evidence (I or II-1) directly linked to health outcome Fair: High grade evidence (I or II-1) linked to intermediate outcome or Moderate grade evidence (II-2 or II-3) directly linked to health outcome Poor: Level III evidence or no linkage of evidence to health outcome Net Effect of Intervention Substantial:
Moderate:
Small:
Zero or Negative:
Grade of Recommendation A: A strong recommendation that the intervention is always indicated and acceptable B: A recommendation that the intervention may be useful/effective C: A recommendation that the intervention be considered D: A recommendation that a procedure may be considered not useful/effective, or may be harmful I: Insufficient evidence to recommend for or against; the clinician will use clinical judgment |
UMHS (2006) |
Levels of evidence reflect the best available literature in support of an intervention or test:
|
The United States Preventive Services Task Force (USPSTF), Department of Veterans Affairs, Department of Defense (VA/DoD), and University of Michigan Health System (UMHS), present recommendations for tobacco use cessation and prevention. The organizations provide explicit reasoning behind their judgments and rate the evidence upon which their recommendations are based.
All of the guidelines included in this synthesis utilized to some degree, evidence and recommendations released in 2000 by the U.S Public Health Service (PHS). For instance, UMHS utilized evidence derived from literature searches of both the 1996 Agency for Health Care Policy and Research (now the Agency for Healthcare Research and Quality [AHRQ]) guideline and the 2000 PHS guideline (both of which are now considered out of date). UMHS also supplemented the supporting evidence for their recommendations with subsequently published information. USPSTF likewise based its recommendations on the evidence provided in the 2000 PHS document including more recently published literature. The VA/DoD guideline refers often to the PHS guideline but has also based its recommendations on an extensive review of more recent literature.
Although all groups provide recommendations on identification of tobacco users and the benefits of counseling and adjunctive pharmacologic treatment for tobacco use, VA/DoD provides the most extensive and comprehensive review, presenting detailed outlines for both brief and intensive strategies to be used by clinicians for tobacco use intervention. VA/DoD also emphasizes a "Population Health" strategy that promotes primary-care based treatment and prevention.
The recommendations for tobacco use cessation and prevention are in almost total concurrence for all three guideline groups. The "Five A" behavioral counseling framework of asking (identifying users), advising (urging users to quit), assessing (determining users' willingness to quit), assisting (through counseling or drug therapy), and arranging for follow-up is universally recommended. UMHS includes a referral in their framework, indicating that if the patient is interested in quitting within 30 days, he or she should be referred to a tobacco treatment specialist or other tobacco cessation program.
The guidelines are in general agreement regarding the need to identify tobacco users during routine clinic visits. Most groups recommend the use of a chart or sticker system to label a patient as a user or former user of tobacco.
All of the guidelines agree on the effectiveness of counseling as a means for clinicians to modify behavior and address tobacco dependence in their patients. All guidelines agree that advice to patients should be "clear," "strong," and "personalized" and should include a discussion of the health benefits of quitting, self-help materials, and referral to community groups, if necessary. Each of the guidelines also agrees that patients who do not wish to quit should receive motivational interventions (e.g., the 5 R's: relevance, risks, rewards, roadblocks, and repetition). The importance of frequent and/or intensive counseling is also stressed by all of the organizations. In particular, the dose-response relationship between treatment intensity and abstinence from tobacco use is emphasized.
The use of nicotine replacement therapy (NRT) as an adjunct to counseling is endorsed by all three guideline groups, except in special circumstances. Bupropion is also recommended by all groups as either first-line or second-line medication. Nortriptyline is recognized as a second-line treatment by all three groups. UMHS recommends clonidine as a second-line treatment in patients unwilling or unable to use NRT or bupropion or who fail on first-line therapy. VA/DoD likewise state that clonidine may be considered on a case-by-case basis after first-line treatments have been used or considered, and should only be used under the supervision of a physician. USPSTF states that clonidine may be considered as pharmacotherapy because it results in higher smoking cessation rates when compared with placebo, although its use may be limited by side effects.
There is also general agreement between the groups with respect to the efficacy of combination NRT. All three groups note that studies with combination NRT suggest improved efficacy compared with single forms of NRT. UMHS, however, notes that, given the additional cost of dual therapies and limited benefit, combining NRT is best reserved for highly addicted smokers with several previous failed quit attempts.
There are some disagreements on the use of drug therapy in pregnant women and in children and adolescents, and these differences are also discussed below.
The need for follow-up to prevent and treat relapses is acknowledged by UMHS and VA/DoD (USPSTF does not provide any specific recommendations in this area).
VA/DoD also emphasizes the need for clinicians to help prevent the initiation of tobacco use in children and adolescents through direct counseling or by participation in school-based or community programs.
VA/DoD offers specific recommendations on counseling to parents on the need to limit children's exposure to second-hand smoke. UMHS and VA/DoD state that the negative effects of passive smoking should be emphasized in trying to motivate smokers to quit.
UHMS and VA/DoD address special populations in their guidelines. Both groups agree that these special populations can benefit from many of the same treatments as the general population, but that treatment can be improved by recognizing the problems or concerns of the individual.
The three groups that provide specific recommendations on counseling and treatment of child and adolescent tobacco users differ somewhat in their approach. VA/DoD states that adolescents who use tobacco and are interested in quitting should be offered counseling and behavioral interventions that were developed for adolescents. They note however that interventions shown to be effective with adults may also be considered with adolescents.
VA/DoD recommends adjunctive pharmacotherapy but only when the clinician has evidence that the adolescent is nicotine dependent and is willing to quit. UMHS states that the same counseling and treatment strategies used in adults can be applied to adolescents; however, they admit that there is limited evidence regarding the efficacy of brief clinician interventions in treating tobacco use in adolescence. They concede that in many cases, "expert opinion rather than empirical data is used to guide clinical interventions for young smokers." USPSTF also states that there is no evidence for the efficacy of cessation programs in young people. USPSTF therefore does not recommend for or against any routine interventions in the primary care setting for screening or treatment of children or adolescents for tobacco use.
Although all of the groups strongly endorse smoking cessation interventions in pregnant women who smoke, they differ in their recommendations concerning use of pharmacologic therapy. VA/DoD (through DoD/VA Clinical Practice Guideline for Management of Uncomplicated Pregnancy) makes no recommendations either for or against drug therapy during pregnancy. UMHS notes that, while few studies have addressed NRTR or bupropion in pregnancy directly, research has shown that less nicotine and fewer metabolites cross the placenta with NRT than with smoking. Therefore, they advise cautious use of bupropion with NRT (especially nicotine gum) after reviewing risks and benefits with the patient. For breastfeeding mothers, UMHS states that data supports the use of bupropion plus NRT in nursing mothers, with increased cessation rates. They note that it is not known whether varenicline is excreted in human milk.
USPSTF also cites the lack of evidence on the safety and efficacy of pharmacotherapy for the pregnant woman, the fetus, or the nursing mother and child. Therefore, USPSTF makes no recommendations for or against pharmacotherapy during pregnancy, but advises that "pharmacotherapy for pregnant women may be considered when the likelihood of quitting and its potential benefits outweigh the risks of the therapy and continued smoking."
This Synthesis was prepared by ECRI on January 22, 2001 and reviewed by the guideline developers as of June 11, 2001. It was modified by ECRI on January 25, 2005 and reviewed by the guideline developers as of March 14, 2005. It was updated in March 2005 to include the 2004 VA/DoD guideline and was reviewed by the developer as of March 17, 2005. This Synthesis was updated on November 9, 2005 following the withdrawal of the PHS guideline from the NGC Web site. This synthesis was updated in December 2006 to update the UMHS recommendations. This synthesis was updated most recently on December 6, 2007 to remove recommendations from SMOH and NZGG.
Internet citation: National Guideline Clearinghouse (NGC). Guideline synthesis: Tobacco use cessation and prevention. In: National Guideline Clearinghouse (NGC) [website]. Rockville (MD): 2001 Jul 29 (revised 2007 Dec). [cited YYYY Mon DD]. Available: http://www.guideline.gov.